AstraZeneca, Daiichi Sankyo still need key overall survival results on TROP2 ADC in breast, lung cancer: #ESMO23

Kyle LaHucik

Senior Reporter

MADRID — Headed into the year’s second-largest cancer conference, expectations were a little subdued for AstraZeneca’s next big bet on antibody-drug conjugates. The pharma’s Daiichi Sankyo …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca, Daiichi Sankyo still need key overall survival results on TROP2 ADC in breast, lung cancer: #ESMO23

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

As­traZeneca, Dai­ichi Sankyo still need key over­all sur­vival re­sults on TROP2 ADC in breast, lung can­cer: #ES­MO23

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

AstraZeneca, Daiichi Sankyo still need key overall survival results on TROP2 ADC in breast, lung cancer: #ESMO23

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra